Paclitaxel / EMT Cancer Research Results

PacT, Paclitaxel: Click to Expand ⟱
Features:
Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.


Paclitaxel – Cancer Pathway Matrix

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization → Mitotic arrest Mitotic progression ↓; spindle dynamics impaired; cell division blocked Proliferating normal cells affected R, G Core cytotoxic mechanism Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2 Spindle assembly checkpoint activation Prolonged mitotic arrest → mitotic catastrophe or apoptosis Checkpoint stress in dividing tissues R, G Mitotic stress execution Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3 Intrinsic apoptosis (mitochondrial pathway) Caspase activation ↑; BAX/mitochondrial signaling engaged (context) Limited unless stressed G Cell death execution Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4 ROS generation (secondary) ROS ↑ (context-dependent); oxidative stress amplification Oxidative stress possible in sensitive tissues R, G Stress amplifier ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5 Nrf2 antioxidant response (adaptive) Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential Protective antioxidant signaling G Adaptive resistance axis Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6 Drug resistance mechanisms P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring — G Treatment failure driver Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7 Myelosuppression — Neutropenia risk ↑ G Dose-limiting toxicity Bone marrow suppression is a primary clinical constraint.
8 Peripheral neuropathy — Sensory neuropathy risk ↑ G Dose-limiting toxicity Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)



EMT, Epithelial-Mesenchymal Transition: Click to Expand ⟱
Source:
Type:
Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin.
EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin).
EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis.
Scientific Papers found: Click to Expand⟱
814- GAR,  PacT,    Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model
- in-vivo, BC, NA
Apoptosis↑, TumCCA↑, EMT↓, TumCI↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,  

Migration ⓘ

TumCI↓, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: EMT, Epithelial-Mesenchymal Transition
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:182  Target#:96  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page